(1992) The ATP-sensitive potassium channel is a key component in protecting the heart from ischemic injury and mediates ischemic preconditioning of the heart. (Garrett Gross, PhD, and John Auchampach, PhD, Pharmacology and Toxicology)
(1995) Opioid drugs, such as morphine, have powerful cardioprotective properties and may reduce the severity of cardiac damage in patients with a heart attack. (Garrett Gross, PhD, and Joel Schultz, PhD, Pharmacology and Toxicology)
(1996) Identification of epoxyeicosatrienoic acids as endogenous endothelial vasodilators (William B. Campbell, PhD, Pharmacology and Toxicology)
(1998) Identified novel endothelial lipoxyenase metabolites that dilate arteries and regulate blood pressure (Sandra Pfister, PhD and William B. Campbell, PhD, Pharmacology and Toxicology)
(2002) Discovery of specific epoxyeicosatrienoic acid agonists and antagonists (Kathryn Gauthier, PhD, John R. Falck, PhD and William B. Campbell, PhD, Pharmacology and Toxicology)
(2003) Discovered that infra-red light from Light Emitting Diodes reverse retinal damage caused by ingestion of methanol. (Janis Eells, PhD, Pharmacology and Toxicology)
(2004) Identification of 2-arachidonylglycerol as an endogenous inhibitor of prostate cancer cell invasion (Kasem Nithipatikom, PhD, Pharmacology and Toxicology)
(2004) Cardiac cytochrome P450 omega-hydroxylase contributes to heart injury following ischemia and omega hydroxylase inhibitors are cardioprotective (Garrett Gross, PhD and Kasem Nitipatikom, PhD Pharmacology and Toxicology)
(2004) Endocannabinoid pathways in the brain reduce stress and drugs that increase endocannabinoids represent new treatments for depression and post-traumatic stress disorders. (Cecilia Hillard, PhD, Pharmacology and Toxicology and Neuroscience Research Center)
(2006) Cardiac cytochrome P450 epoxygenase protects the heart from ischemic injury through synthesis of epoxyeicosatrienoic acids. (Garrett Gross, PhD and Kasem Nithipatikom, PhD, Pharmacology and Toxicology)
(2006) Discovered dramatic differences in way adults, infants, and children process drugs. (Ronald Hines, PhD, Pharmacology and Toxicology)
(2008) SmgGDS is a protein that increases the growth of lung, prostate and breast tumors and reducing SmgGDS slows the growth of cancer cells and diminishes tumor formation (Carol L. Williams, PhD, Pharmacology and Toxicology)
(2009) Inhibition of soluble epoxide hydrolase lowers blood pressure and protects the kidney from damage in hypertension (John D. Imig, PhD, Pharmacology and Toxicology)
(2011) Invented novel epoxyeicosatrienoic acid (EET) analogs and soluble epoxide hydrolase inhibitors (SEHI) with therapeutic value for the treatment of inflammation and of cardiovascular, renal and other diseases. (John Imig, PhD, and William Campbell, PhD, Pharmacology & Toxicology, Camille Falck, PhD, UT Southwestern)
(2012) Comparing whole genome sequences for non-small cell lung tumors and adjacent normal tissue, alterations in 5 novel genes were discovered and may lead to new treatments for lung cancer. (Ming You, MD, PhD, Pharmacology and Toxicology and Cancer Center)
(2012) A novel gene called CSMD3 is the most frequently mutated gene in lung cancer. (Ming You, MD, PhD, Pharmacology and Toxicology and Cancer Center)
(2013) Discovered a way to block adenosine, produced by tumor cells, which may be responsible for signaling lung, breast, and pancreatic cancer metastasis. (Carol L. Williams, PhD, Pharmacology and Toxicology)
Learn more about MCW's history
